1. Near-Infrared Plasmonic Assemblies of Gold Nanoparticles with Multimodal Function for Targeted Cancer Theragnosis.
- Author
-
Kim SE, Lee BR, Lee H, Jo SD, Kim H, Won YY, and Lee J
- Subjects
- Cell Proliferation, DNA chemistry, DNA metabolism, DNA-Binding Proteins chemistry, DNA-Binding Proteins metabolism, Endocytosis, Humans, Lung Neoplasms diagnostic imaging, Metal Nanoparticles chemistry, Transcription Factors chemistry, Transcription Factors metabolism, Tumor Cells, Cultured, Gold chemistry, Lung Neoplasms therapy, Metal Nanoparticles administration & dosage, Photoacoustic Techniques methods, Phototherapy, Spectroscopy, Near-Infrared methods
- Abstract
Here we report a novel assembly structure of near-infrared plasmonic gold nanoparticles (AuNPs), possessing both photoacoustic (PA) and photothermal (PT) properties. The template for the plasmonic AuNP assembly is a bioconjugate between short double-strand DNA (sh-dsDNA) and human methyl binding domain protein 1 (MBD1). MBD1 binds to methylated cytosine-guanine dinucleotides (mCGs) within the sequence of sh-dsDNA. Hexahistidine peptides on the engineered MBD1 function as a nucleation site for AuNP synthesis, allowing the construction of hybrid conjugates, sh-dsDNA-MBD1-AuNPs (named DMAs). By varying the length of sh-dsDNA backbone and the spacer between two adjacent mCGs, we synthesized three different DMAs (DMA_5mCG, DMA_9mCG, and DMA_21mCG), among which DMA_21mCG exhibited a comparable photothermal and surprisingly a higher photoacoustic signals, compared to a plasmonic gold nanorod. Further, epidermal growth factor receptor I (EGFR)-binding peptides are genetically attached to the MBD1 of DMA_21mCG, enabling its efficient endocytosis into EGFR-overexpressing cancer cells. Notably, the denaturation of MBD1 disassembled the DMA and accordingly released the individual small AuNPs (<5 nm) that can be easily cleared from the body through renal excretion without causing accumulation/toxicity problems. This DMA-based novel approach offers a promising platform for targeted cancer theragnosis based on simultaneous PA imaging and PT therapy.
- Published
- 2017
- Full Text
- View/download PDF